Cofetuzumab Pelidotin for Non-Small Cell Lung Cancer

Stanford Univ School Medicine /ID# 213450, Stanford, CA
Non-Small Cell Lung Cancer+1 More ConditionsCofetuzumab Pelidotin - Drug
All Sexes

Study Summary

This trial is testing a new drug to treat a certain type of lung cancer that has come back.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to approximately 3 years

Year 3
Duration of Response (DOR)
Objective Response Rate (ORR)
Overall Survival (OS)
Progression Free Survival (PFS)

Trial Safety

Phase-Based Safety

1 of 3

Side Effects for

PF-06647020 2.1 mg/kg (Q2W Regimen)
33%Decreased appetite
33%Neuropathy peripheral
33%Peripheral sensory neuropathy
33%Infusion related reaction
This histogram enumerates side effects from a completed 2019 Phase 1 trial (NCT02222922) in the PF-06647020 2.1 mg/kg (Q2W Regimen) ARM group. Side effects include: Alopecia with 100%, Diarrhoea with 33%, Decreased appetite with 33%, Arthralgia with 33%, Myalgia with 33%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Cofetuzumab Pelidotin
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Cofetuzumab Pelidotin · No Placebo Group · Phase 1

Cofetuzumab Pelidotin
Experimental Group · 1 Intervention: Cofetuzumab Pelidotin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 3 years

Who is running the clinical trial?

PfizerIndustry Sponsor
4,406 Previous Clinical Trials
25,778,415 Total Patients Enrolled
AbbVieLead Sponsor
873 Previous Clinical Trials
479,950 Total Patients Enrolled
AbbVie Inc.Study DirectorAbbVie
264 Previous Clinical Trials
100,834 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
325 Previous Clinical Trials
125,142 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has Cofetuzumab Pelidotin been sanctioned by the FDA?

"There is limited clinical data in regards to the safety and efficacy of Cofetuzumab Pelidotin, thus it has been assigned a score of 1." - Anonymous Online Contributor

Unverified Answer

How widely available is this research endeavor?

"Patients are being enrolled at Stanford Univ School Medicine /ID# 213450 (Stanford, CA), Virginia Cancer Specialists /ID# 216427 (Fairfax, VA) and Sylvester Comprehensive Cancer /ID# 216433 (Miami, FL). Additionally there are 18 other sites participating." - Anonymous Online Contributor

Unverified Answer

Is enrollment for the experiment still available at this time?

"Affirmative. data reveals that this research initiative, which was initially uploaded to the website on February 13th 2020, is presently admitting participants. Sixty individuals must be recruited from 18 distinct healthcare centres." - Anonymous Online Contributor

Unverified Answer

How many persons are being included in this investigation?

"Affirmative. holds evidence that this clinical trial is still ongoing, having been initially posted on February 13th 2020 and updated most recently on November 24th 2022. A total of 60 patients are being sought after by 18 different medical sites across the country." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.